scholarly journals Current and future prospects for the global biotechnology industry

10.5912/jcb68 ◽  
1969 ◽  
Vol 10 (2) ◽  
Author(s):  
Faiz Kermani ◽  
Pietro Bonacossa
Keyword(s):  
New Zealand ◽  
Recombinant Dna ◽  
Biotechnology Industry ◽  
New Drugs ◽  
Future Prospects ◽  
Recombinant Dna Technology ◽  
The Past ◽  
The Usa ◽  
Biotechnology Companies ◽  
Dna Technology

The number of biotechnology compounds has been increasing steadily over the past 20 years, reflecting the key contribution that biotechnology is now making to healthcare. Recombinant DNA technology has been used to develop a number of therapeutic proteins, including antibodies, cytokines, hormones and vaccines for use in tackling and diagnosing a range of disorders. Worldwide there are more than 4,000 specialised biotechnology companies. The most well-known companies are located in the USA and Europe, but there are significant companies emerging in Canada, Australia, New Zealand and throughout Asia – particularly in Japan. Most of these companies are small in size and limited when it comes to finances and this has had an impact on the output of the industry in terms of new drugs.

Microbial Production of Recombinant Rennet

2018 ◽  
pp. 222-233 ◽  
Author(s):  
Zumrut Begum Ogel
Keyword(s):  
Proteolytic Activity ◽  
Recombinant Dna ◽  
Microbial Production ◽  
Recombinant Dna Technology ◽  
Aspartic Proteases ◽  
The Past ◽  
Traditional Cheese ◽  
Dna Technology ◽  
Cheese Products ◽  
Recombinant Dna Techniques

Rennet, traditionally obtained from calves, is non-vegeterian and unethical due to the slaughter of unweaned animals. Chymosin is highly specific to the Phe105-Met106 bond of κ-casein and has low proteolytic activity. Microbial aspartic proteases can partly replace chymosin. However, recombinant DNA technology has allowed chymosin itself to be produced by bacteria, yeast, and molds. Not only rennet from calf, but from animals like goat kid, lamb, buffalo, camel, and others can be used in cheesemaking. Chymosins of these animals can be cloned and successfully expressed in microorganisms and can be employed in the production of novel as well as traditional cheese products from the milk of camel, goat, and even horse and donkey. This chapter outlines the recombinant DNA techniques applied over the past few years to improve the microbial production of recombinant rennet, from animals and plants.

scholarly journals Role of Recombinant DNA Technology to Improve Life

2016 ◽  
Vol 2016 ◽  
pp. 1-14 ◽  
Author(s):  
Suliman Khan ◽  
Muhammad Wajid Ullah ◽  
Rabeea Siddique ◽  
Ghulam Nabi ◽  
Sehrish Manan ◽  
...  
Keyword(s):  
Target Genes ◽  
Recombinant Dna ◽  
Human Life ◽  
Product Yield ◽  
Past Century ◽  
Recombinant Dna Technology ◽  
The Past ◽  
Genetic Modifications ◽  
Dna Technology

In the past century, the recombinant DNA technology was just an imagination that desirable characteristics can be improved in the living bodies by controlling the expressions of target genes. However, in recent era, this field has demonstrated unique impacts in bringing advancement in human life. By virtue of this technology, crucial proteins required for health problems and dietary purposes can be produced safely, affordably, and sufficiently. This technology has multidisciplinary applications and potential to deal with important aspects of life, for instance, improving health, enhancing food resources, and resistance to divergent adverse environmental effects. Particularly in agriculture, the genetically modified plants have augmented resistance to harmful agents, enhanced product yield, and shown increased adaptability for better survival. Moreover, recombinant pharmaceuticals are now being used confidently and rapidly attaining commercial approvals. Techniques of recombinant DNA technology, gene therapy, and genetic modifications are also widely used for the purpose of bioremediation and treating serious diseases. Due to tremendous advancement and broad range of application in the field of recombinant DNA technology, this review article mainly focuses on its importance and the possible applications in daily life.

From animals in the service of nutrition...to the potential of biotechnology

1997 ◽  
Vol 78 (s2) ◽  
pp. S125-S133
Author(s):  
Judith Hall
Keyword(s):  
Animal Models ◽  
Recombinant Dna ◽  
Human Nutrition ◽  
Western World ◽  
Past Century ◽  
Recombinant Dna Technology ◽  
The Past ◽  
Nutrition Research ◽  
Dna Technology ◽  
Obesity And Cancer

In 1986, in her paper, ‘Animals in the service of human nutrition’, celebrating the award of the E. V. McCollum International Lectureship in Nutrition, Dr Elsie Widdowson observed: ‘Animals have served human nutrition well over the past century.... They are still of great service in human nutrition and may be more essential in the future as proper animal models for human diseases are discovered’. Ten years on, those animal models are an integral part of nutrition research and are providing fundamental tools to study the effects of diet on many of the major diseases of the Western world, including cardiovascular disease, obesity and cancer. Many of these models have been developed through the use of recombinant DNA technology and the expression of normal or mutated genes in the genome of transgenic mice.

The Biotechnology Industry

1998 ◽  
Vol 11 (1) ◽  
pp. 13-18
Author(s):  
Ronald P. Evens
Keyword(s):  
Strategic Alliances ◽  
Recombinant Dna ◽  
Marketing Research ◽  
Biotechnology Industry ◽  
Pharmaceutical Companies ◽  
Research Development ◽  
Recombinant Dna Technology ◽  
Sales And Marketing ◽  
Biotechnology Companies ◽  
Growth And Change

Growth and change are the hallmarks of the developing biotechnology industry. Since the first approval of a biological product in 1982, over 40 biologicals, many of them medical breakthroughs, have been brought to market. The majority of biotechnology companies focus on developing human therapeutic agents, but about 25 percent of biotechnology companies focus on the diagnostic area, using monoclonal antibody technology, polymerase chain reaction (PCR) technology, and genetics to provide advances in diagnosis and disease monitoring. Structurally, few biotechnology firms are fully integrated companies with full capabilities in research, development, manufacturing, and sales and marketing. Many pursue strategic alliances with other companies to enhance their capabilities in research, development, and sales and marketing. Research alliances between companies and universities are also frequently used to enhance research capabilities. As the industry has matured, consolidation has occurred, with major pharmaceutical companies purchasing biotechnology companies and biotechnology companies merging to expand their capabilities. Research investment, as a percentage of gross sales, continues to be very high for biotechnology companies compared with traditional pharmaceutical companies. The cost of drug development is high, but the probability of approval appears to be somewhat better in the biotechnology field compared with traditional pharmaceuticals. Today, the biotechnology product pipeline is rich, with between 400 to 700 products in various stages of clinical development. Technology developments beyond recombinant DNA technology and monoclonal antibodies, such as antisense, genomics, and combinatorial chemistry, will lead to additional therapeutic and diagnostic breakthroughs.

scholarly journals Biotin Production by Using Recombinant DNA Technology

1992 ◽  
Vol 38 (Special) ◽  
pp. 263-266
Author(s):  
O. IFUKU ◽  
S. HAZE ◽  
J. KISHIMOTO ◽  
M. YANAGI
Keyword(s):  
Recombinant Dna ◽  
Recombinant Dna Technology ◽  
Dna Technology

Introduction to Recombinant DNA

PEDIATRICS ◽  
1984 ◽  
Vol 74 (3) ◽  
pp. 408-411
Author(s):  
Stephen D. Cederbaum
Keyword(s):  
Inborn Errors Of Metabolism ◽  
Recombinant Dna ◽  
Phenylalanine Hydroxylase ◽  
Professional Lives ◽  
Recombinant Dna Technology ◽  
Inborn Errors ◽  
Dna Technology ◽  
Basic Vocabulary ◽  
The Moment ◽  
The Many

Seldom has a scientific or biomedical break-through evoked the awe, controversy, or sheer incredulity that has accompanied the developments in the field of recombinant DNA technology or more popularly, gene cloning and genetic engineering. Now little more than one generation after Avery, et al1 demonstrated that genes were encoded in DNA and Watson and Crick2 interpreted the structure of these molecules, genes are being cut, manipulated, and recombined to produce unprecedented new insights into genetics and molecular biology and the prospect of gene therapy. These developments have not occurred without anxiety to both scientists and laymen. At the moment, neither the most apocalyptic fears nor the most optimistic dreams appear to be imminent, although I believe that the dreams are closer to fulfillment than the fears. Recombinant DNA technology is already having great impact in hematology, oncology, endocrinology, immunology, and infectious disease and will soon play an important role in other medical subspecialities as well. In none, however, will it have quite the same impact as in genetics because DNA is the material that genetics "is all about." The cloning and study of phenylalanine hydroxylase is one of the first instances in which this technology has important implications in the diseases traditionally classified as inborn errors of metabolism. In order to understand and appreciate the presentation by Woo on phenylalanine hydroxylase as well as the many future papers that will play so vital a role in all of our professional lives, it is necessary to acquire the basic vocabulary of the field.

Sign in / Sign up

Export Citation Format

Share Document